• Lower mortality with SGLT2 inhibitors, GLP-1 agonists than DPP-IV inhibitors in diabetes

    6 monthes ago - By Healio

    Sean L. Zheng
    Among patients with type 2 diabetes, the use of SGLT2 inhibitors and GLP-1 receptor agonists is associated with lower risk for all-cause mortality and cardiovascular mortality vs. DPP-IV inhibitors, according to a systematic review of randomized controlled trials published in JAMA.
    “Doctors are now presented with many treatment options for their patients with type 2 diabetes,” Sean L. Zheng, BM BCh, MA, MRCP, told Endocrine Today. “The focus of diabetes management has been the reduction of glycated hemoglobin levels. Recent research suggests that some of
    Read more ...

     

  • Artificial Pancreas 'Safe' for Treating Type 1 Diabetes

    Artificial Pancreas 'Safe' for Treating Type 1 Diabetes

    6 monthes ago - By Medindia Health

    An artificial pancreas device systems is a smartphone-sized device that helps measure blood sugar levels and is found to be a safe and effective treatment approach for people with type 1 diabetes.
    Read more ...